Compare Amgen, Inc. (AMGN) vs Dominion Energy Inc (D) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Dominion Energy Inc — how do they compare? Amgen, Inc. trades at $363.49 (market cap $196.12B), while Dominion Energy Inc trades at $70.23 (market cap $61.64B). The key difference: Amgen, Inc. is far larger — about 3.2× Dominion Energy Inc's market cap, and Dominion Energy Inc pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| AMGN | D | |
|---|---|---|
Market Cap | $196.12B | $61.64B |
Sector | Health | Utilities |
52-Week High | $388.16 | $70.08 |
52-Week Low | $271.18 | $56.55 |
Enterprise Value | $241.41B | $114.04B |
Dividend Yield | 2.77% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Dominion Energy (D) trades at $70.08, up 0.91% today, near its consensus price target of $69.50. The stock shows bullish technical signals with strong moving average support and recent earnings beats. Revenue grew to $16.51B in 2025 with net income margin expanding to 18.16%. The pending $66.8B acquisition by NextEra Energy dominates news flow, positioning Dominion as key infrastructure for AI data center power demand.
Investment outlook balances acquisition premium potential against regulatory approval risks. Strong profitability trends and strategic positioning in power infrastructure support upside, but deal uncertainty and high debt levels pose near-term volatility. Wall Street sentiment is cautious with 59% hold ratings, reflecting wait-and-see approach pending merger resolution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Dominion Energy Inc
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.
Read more on D →
